Stimulant Withdrawal & Recovery: Methamphetamine, Cocaine, Amphetamines, the Crash, Depression, Sleep, and Evidence-Based Treatment

Executive summary

Stimulant withdrawal is real, but its danger profile is different from alcohol or benzodiazepine withdrawal. Uncomplicated withdrawal from methamphetamine, amphetamine, or cocaine is usually dominated by sleepiness or disrupted sleep, profound fatigue, increased appetite, depressed mood, anhedonia, irritability, anxiety, psychomotor slowing or agitation, and craving rather than seizures or delirium caused by withdrawal itself [1-6].

That does not make stimulant withdrawal harmless. Suicide risk can increase as intoxication wanes and acute withdrawal begins, and psychosis, severe depression, agitation, dehydration, trauma, chest pain, arrhythmia, stroke, hyperthermia, or an opioid co-exposure can turn a presumed “crash” into an emergency [1,2,26,32-36].

The word crash is useful but imprecise. After prolonged wakefulness or repeated stimulant use, some people experience an early period of hypersomnia, exhaustion, irritability, increased appetite, and low mood. ASAM/AAAP notes that many patients experience roughly the first day of somnolence and irritability after abrupt reduction, while methamphetamine research describes a broader acute withdrawal syndrome that can remain clinically important over the first week and then decline into a lower-grade subacute phase [1,3].

There is no validated universal “dopamine reset” clock. Recovery depends on the stimulant, route, pattern of use, sleep deprivation, dose exposure, psychiatric illness, nutrition, co-use, and individual neurobiology. Depression, anxiety, insomnia, paranoia, craving, and cognitive problems can persist for weeks or months in some patients [1,27-30].

There is also no FDA-approved medication specifically for stimulant withdrawal or stimulant use disorder as of 2026 [1,4,5,13-16,30]. Acute withdrawal care is therefore primarily supportive and symptom-focused. For long-term stimulant use disorder (StUD), the strongest behavioral evidence is for contingency management, which ASAM/AAAP calls the current standard of care and which multiple systematic reviews and meta-analyses associate with better stimulant abstinence outcomes [1,17-25].

Several medications have meaningful but narrower evidence. Extended-release naltrexone plus bupropion improved response rates in the ADAPT-2 methamphetamine trial, although most participants still did not meet the stringent response definition [9,10]. Mirtazapine reduced methamphetamine-positive urine tests in two trials among men and transgender women who have sex with men [11,12]. Other off-label options may be considered in selected patients, but the evidence is not equivalent to an approved, broadly effective medication [1,13-16,30].

Do-not-miss: when a “stimulant crash” needs urgent evaluation

Urgent medical or psychiatric assessment is warranted for:

• suicidal thoughts, intent, a suicide attempt, or inability to remain safe;
• severe depression with inability to eat, drink, care for oneself, or maintain basic functioning;
• hallucinations, paranoia, mania, severe agitation, or behavior creating danger to self or others;
• chest pain, severe shortness of breath, fainting, or dangerous palpitations;
• sudden weakness, facial droop, severe headache, speech difficulty, or other stroke symptoms;
• very high temperature, severe muscle rigidity, collapse, or profound agitation;
• seizure;
• severe dehydration or prolonged inability to take fluids;
• altered consciousness or unexpectedly slow breathing;
• suspected opioid exposure or an overdose pattern inconsistent with a pure stimulant effect;
• pregnancy with significant intoxication, withdrawal, hypertension, or psychiatric instability.

ASAM/AAAP specifically emphasizes monitoring suicidality as stimulant intoxication wanes and acute withdrawal begins [1]. A person becoming quieter or sleepier after a stimulant binge should not automatically be assumed to be medically safe.

Intoxication, comedown, crash, withdrawal, and recovery are not the same phase

These terms are often blurred together.

Intoxication is the period of active stimulant effect: increased wakefulness, sympathetic activation, decreased appetite, and sometimes euphoria, anxiety, compulsive behavior, agitation, or psychosis.

Comedown is informal language for the transition as acute stimulant effects fade.

Crash usually refers to the early exhaustion phase after heavy or prolonged use, often characterized by sleepiness, fatigue, low mood, and increased appetite.

Acute withdrawal is the broader syndrome following abrupt cessation or substantial reduction after repeated exposure.

Post-acute withdrawal/recovery refers to persistent sleep, mood, craving, cognitive, and functional symptoms after the acute syndrome has largely resolved.

These phases overlap. They should not be converted into a rigid four-stage calendar.

Dependence is not stimulant use disorder

A person can develop physiological adaptation to stimulants without meeting criteria for addiction.

Tolerance is reduced effect after repeated exposure.

Withdrawal is the syndrome produced when exposure falls.

Craving is a motivational state and may persist long after acute withdrawal.

Stimulant use disorder involves impaired control, compulsive use, hazardous use, continued use despite harm, and related behavioral features.

Prescribed stimulant treatment for ADHD is therefore not automatically equivalent to stimulant use disorder, even if stopping the medication produces fatigue, sleepiness, appetite change, or return of ADHD symptoms [31].

Why stimulant withdrawal happens

Cocaine, amphetamine, methamphetamine, and prescription stimulants all increase catecholaminergic signaling, but they do so through different pharmacology.

Cocaine primarily blocks reuptake transporters, including the dopamine transporter.

Amphetamine and methamphetamine enter monoamine neurons and promote release/reversal of monoamine transport, with methamphetamine producing particularly potent effects on dopamine and norepinephrine systems.

Repeated high-intensity exposure alters reward learning, stress systems, sleep/arousal, dopamine signaling, executive control, cue reactivity, and other networks [27-30].

When exposure falls, the person is not simply “low on dopamine.” The clinical syndrome reflects:

• receptor/transporter adaptations;
• sleep deprivation and rebound sleep pressure;
• stress-system dysregulation;
• depleted behavioral reward;
• conditioned cue/craving networks;
• nutritional and hydration deficits;
• psychiatric comorbidity;
• the aftermath of prolonged sympathetic activation.

That complexity is why a single “dopamine replenishment timeline” is scientifically misleading.

The core withdrawal symptom map

Sleep and energy

• hypersomnia during the early crash in many patients;
• profound fatigue;
• later fragmented sleep or insomnia;
• vivid dreams;
• altered sleep timing.

Mood

• depressed mood;
• dysphoria;
• anhedonia;
• irritability;
• anxiety;
• emotional flattening.

Appetite and body

• increased appetite;
• low physical energy;
• aches or generalized discomfort;
• dehydration or nutritional depletion carried over from active use.

Cognition

• poor concentration;
• slowed thinking;
• reduced motivation;
• executive-function difficulty;
• impaired decision-making.

Reward and craving

• strong cue-induced craving;
• reduced pleasure from ordinary activities;
• urges to use stimulant simply to feel “normal” or awake.

Psychiatric

• paranoia or psychotic symptoms that may persist from intoxication;
• agitation;
• trauma-related symptoms;
• suicidality.

Not every person experiences all domains.

Methamphetamine withdrawal

Methamphetamine withdrawal is the best-characterized amphetamine-type withdrawal syndrome.

In a prospective study, withdrawal severity was highest early and declined substantially across an acute phase of roughly the first week, followed by a lower-severity subacute period extending at least another couple of weeks [3].

Prominent symptoms included:

• increased sleep;
• increased appetite;
• depression-related symptoms;
• anxiety;
• craving.

ASAM/AAAP also recognizes post-acute depression, anxiety, insomnia, and paranoia lasting weeks to months in some patients [1].

Why methamphetamine recovery can feel neurologically “flat”

Methamphetamine use disorder is associated, at a group level, with measurable differences in cognition and brain imaging [27-30].

But those findings should not be translated into “your dopamine system is permanently destroyed.”

A 2026 meta-analysis found medium-to-large average cognitive deficits across multiple domains in people with methamphetamine use disorder, but the evidence certainty for abstinence-related recovery trajectories was very low because much of the literature is cross-sectional [28].

The correct message is:

• cognitive difficulty is common enough to take seriously;
• recovery can be slow and variable;
• existing studies do not provide a precise individual recovery clock.

Cocaine withdrawal

Cocaine has a shorter pharmacokinetic profile than methamphetamine, so the transition from intoxication to crash can feel abrupt.

Common features include:

• fatigue;
• depressed mood;
• increased appetite;
• sleep changes;
• psychomotor slowing or agitation;
• vivid unpleasant dreams;
• craving [6-8].

Cocaine withdrawal has historically been described as a crash followed by withdrawal and extinction phases, but later evidence does not support assuming that every person passes through a fixed sequence.

Cocaine and sleep: subjective recovery can be deceptive

Cocaine research has produced an important finding: people may report that sleep feels better during early abstinence while objective sleep measures remain disrupted [7,8].

That mismatch matters because poor sleep can impair attention, impulse control, mood, and treatment engagement even when the patient says “I'm sleeping fine now.”

Amphetamine withdrawal

Amphetamine withdrawal overlaps strongly with methamphetamine withdrawal:

• fatigue;
• hypersomnia or insomnia;
• increased appetite;
• depressed mood;
• irritability;
• psychomotor slowing/agitation;
• craving [4,5].

The pharmacology and intensity of exposure still matter. Illicit high-dose amphetamine use, extended binges, and prescribed therapeutic amphetamine are not interchangeable exposures.

Prescription stimulant discontinuation

Prescription amphetamine and methylphenidate deserve separate treatment from illicit stimulant use.

A person stopping a therapeutic stimulant may notice:

• fatigue;
• sleepiness;
• increased appetite;
• lower drive;
• return of untreated ADHD symptoms;
• mood changes in some cases.

That is not automatically evidence of stimulant use disorder.

A 2026 expert consensus on deprescribing stimulants in adults with ADHD emphasizes reassessing diagnosis, benefit, adverse effects, misuse, psychiatric/medical contraindications, and patient context rather than treating all long-term stimulant therapy as something that must be stopped [31].

The evidence base for withdrawal after ordinary therapeutic dosing is far thinner than the literature on chronic high-intensity methamphetamine or cocaine use.

Route and pattern matter

Smoking or injecting a stimulant can produce rapid, high brain concentrations and reinforce repeated dosing differently from slower oral exposure.

Risk is influenced by:

• route;
• dose intensity;
• frequency;
• binge duration;
• sleep deprivation;
• duration of regular use;
• purity and product identity;
• co-use;
• psychiatric vulnerability.

This is why a “grams per day = withdrawal severity” formula would be misleading.

The first day: sleep debt meets neuroadaptation

ASAM/AAAP notes that many patients experience 12–24 hours of somnolence and irritability after abrupt stimulant reduction [1].

That early sleepiness partly reflects accumulated sleep deprivation.

But sleep is not the whole syndrome. Depression, craving, appetite changes, slowed cognition, and psychiatric symptoms can outlast the initial crash.

Someone sleeping for a long period after sustained stimulant use may be experiencing an expected crash—but abnormal breathing, inability to awaken, cyanosis, or other signs of opioid toxicity are not explained by uncomplicated stimulant withdrawal.

Acute withdrawal timeline: useful ranges without fake precision

A practical evidence-based framework is:

The table describes populations, not a personal forecast [1,3-8,27-30].

Depression and anhedonia

Depressed mood is one of the most clinically important stimulant-withdrawal symptoms.

It can range from:

• low energy and reduced pleasure;
• hopelessness;
• marked dysphoria;
• severe major-depression-like symptoms;
• suicidality.

The mechanism cannot be reduced to dopamine alone.

Sleep loss, stress, psychosocial consequences of use, co-occurring depression, and stimulant-induced mood disorders all contribute.

Persistent or severe depression should be assessed and treated rather than dismissed as something that must simply be endured until “dopamine comes back” [1].

Suicide risk can rise as intoxication fades

This is a defining safety issue.

ASAM/AAAP specifically notes that suicidality may increase during waning intoxication and acute withdrawal [1].

Possible reasons include:

• abrupt dysphoria;
• shame or crisis after a binge;
• sleep deprivation;
• paranoia;
• relationship/financial/legal consequences;
• pre-existing depression;
• impulsivity;
• access to lethal means;
• co-use of alcohol or opioids.

A person moving from agitation to exhaustion should not automatically receive less psychiatric attention.

Psychosis: intoxication, withdrawal, persistence, or primary illness?

Methamphetamine and cocaine can produce paranoia, hallucinations, and psychosis.

Symptoms often emerge during intoxication or sleep deprivation, but they can persist into withdrawal and abstinence.

A 2024 systematic review found substantial overlap between methamphetamine-induced psychosis and schizophrenia symptom profiles [26].

That overlap means clinicians should not assume:

• all psychosis in a stimulant user is temporary;
• all persistent psychosis proves schizophrenia;
• stopping the stimulant instantly resolves risk.

ASAM/AAAP recommends treating psychosis or mania when indicated and reassessing its course over time [1].

Anxiety and agitation

Anxiety can appear during both intoxication and withdrawal.

Agitation during active sympathomimetic toxicity is different from the restless dysphoria of a crash.

If agitation is accompanied by:

• extreme hypertension;
• hyperthermia;
• chest pain;
• delirium;
• severe paranoia;
• violent behavior;
• seizure,

the clinical problem may still be intoxication or another emergency rather than uncomplicated withdrawal.

Cardiovascular symptoms are not “withdrawal to push through”

Chest pain, severe hypertension, arrhythmia, stroke symptoms, or collapse can occur around stimulant exposure and require emergency evaluation [1,32].

The risk does not disappear simply because the person says the stimulant is “wearing off.”

Cocaine can cause coronary vasoconstriction and thrombosis. Methamphetamine can produce severe sympathetic stress and chronic cardiomyopathy.

Recovery articles should therefore separate:

• unpleasant withdrawal symptoms;
• complications of recent intoxication;
• long-term stimulant-related disease.

There is no approved medication for acute stimulant withdrawal

A 2022 systematic review/meta-analysis of randomized trials found insufficient evidence for any medication as an established treatment for methamphetamine withdrawal [4].

The older Cochrane amphetamine-withdrawal review reached a similar conclusion [5].

ASAM/AAAP therefore frames withdrawal management around:

• a calm environment;
• sleep and nutrition;
• hydration when needed;
• symptom treatment;
• psychiatric monitoring;
• treatment of psychosis, depression, or insomnia when clinically indicated;
• rapid connection to ongoing StUD treatment [1].

This is very different from alcohol or benzodiazepine withdrawal, where specific medication strategies prevent life-threatening withdrawal complications.

Supportive care is not “doing nothing”

Useful clinical tasks during stimulant withdrawal can include:

• restoring sleep opportunity;
• nutrition;
• hydration;
• treating pain or other medical illness;
• monitoring mood and suicidality;
• treating persistent psychosis;
• addressing anxiety;
• managing severe insomnia after the initial hypersomnia phase;
• evaluating infections and injection complications;
• connecting the patient to continuing treatment.

The purpose is not to sedate every symptom away. It is to make the person safe enough to stay engaged through the period when return-to-use risk is high.

Sleep treatment requires restraint

The initial crash can involve hypersomnia. Later, insomnia may become prominent.

ASAM/AAAP advises caution with sedative-hypnotic medications because creating a new dependence problem can complicate stimulant recovery [1].

Sleep care should consider:

• circadian disruption;
• sleep apnea;
• depression/anxiety;
• stimulant-induced sleep debt;
• caffeine/nicotine;
• environmental instability;
• co-used sedatives.

A sleep medication can be appropriate in selected cases, but “stronger sedation” is not automatically better recovery.

No supplement has established efficacy for stimulant withdrawal

Claims about:

• tyrosine;
• mucuna/L-DOPA;
• megadose vitamins;
• magnesium;
• “dopamine detox” stacks;
• nootropics;
• adaptogens,

often move far beyond clinical evidence.

Nutritional deficits should be corrected. That is different from claiming a supplement accelerates dopamine receptor recovery or prevents relapse.

There is currently no evidence-based supplement protocol that replaces clinical treatment for stimulant withdrawal or StUD.

Contingency management: the strongest treatment evidence

Contingency management (CM) uses tangible reinforcement for objectively verified treatment goals, often stimulant-negative tests or treatment attendance.

This can sound simplistic until the evidence is examined.

ASAM/AAAP calls CM the current standard of care for stimulant use disorder [1].

A 2021 meta-analysis of 157 cocaine-treatment studies found CM was the only treatment category consistently associated with increased likelihood of cocaine-negative urine tests [17].

A methamphetamine-specific systematic review found abstinence benefits in 20 of 21 studies that reported abstinence outcomes [19].

A 2024 meta-analytic evaluation supported CM as an empirically supported drug-use treatment, and a 2025 review found moderate-to-large effects for monosubstance targets [20,21].

This is one of the clearest places where evidence should outrank intuition.

Why incentives can work

CM is not “paying someone to be good.”

It applies behavioral reinforcement to compete with the immediate reinforcement produced by stimulants.

Effective programs typically:

• define a measurable target;
• verify it objectively;
• deliver reinforcement promptly;
• make continued success increasingly valuable;
• reset or modify reinforcement after recurrence according to protocol.

Implementation details matter, which is why very weak incentive programs can underperform well-designed CM.

CBT, community reinforcement, and motivational approaches

CBT can help identify:

• triggers;
• automatic thoughts;
• cue-response patterns;
• high-risk situations;
• coping strategies;
• relapse chains.

The community reinforcement approach builds alternative sources of reward in work, relationships, recreation, and routine.

A network meta-analysis found CM combined with community reinforcement among the strongest psychosocial strategies for cocaine/amphetamine disorders [18].

These approaches can complement rather than replace CM.

Naltrexone plus bupropion for methamphetamine use disorder

The ADAPT-2 trial is one of the most important medication studies in methamphetamine treatment [9].

The combination of injectable extended-release naltrexone and oral extended-release bupropion produced a significantly higher response rate than placebo.

But the absolute response rate remained modest.

That nuance matters.

The trial supports a real treatment signal, not the claim that methamphetamine use disorder now has a broadly effective medication equivalent to methadone/buprenorphine for OUD.

ASAM/AAAP therefore allows clinicians to consider the combination off-label for amphetamine-type stimulant use disorder, with appropriate patient-specific risk assessment [1].

Naltrexone alone is not the same evidence

A 2025 systematic review/meta-analysis found insufficient support for naltrexone monotherapy as a broadly effective treatment for amphetamine-type stimulant use disorder [15].

That is an important distinction.

Evidence for a combination does not automatically transfer to either component alone.

Mirtazapine

Two randomized trials in men and transgender women who have sex with men found reductions in methamphetamine use with mirtazapine plus counseling [11,12].

The later trial also found improvements in some depressive and insomnia measures.

Generalizability is the key limitation.

The participants were drawn from a specific population, and the medication is not FDA-approved for methamphetamine use disorder.

ASAM/AAAP treats mirtazapine as an off-label option that may be considered for amphetamine-type stimulant use disorder, particularly when co-occurring depression or sleep problems make its other effects relevant [1].

Cocaine pharmacotherapy remains a major gap

Dozens of medications have been tested for cocaine use disorder.

A systematic review found low-strength signals for agents such as bupropion, topiramate, or psychostimulants on some abstinence outcomes, while most studied pharmacotherapies were not clearly effective [16].

A larger 2021 meta-analysis found that among treatment categories, CM stood out as consistently associated with objective reductions in cocaine use [17].

As of 2026, there is still no FDA-approved medication for cocaine use disorder [1,30].

Prescription psychostimulants as treatment: specialist territory

Some trials and meta-analyses suggest prescription psychostimulants may help selected patients with stimulant use disorder.

ASAM/AAAP places unusually strong guardrails around this strategy: psychostimulants for StUD should be prescribed by addiction specialists or clinicians with commensurate expertise and capacity for close monitoring [1].

This is not a rationale for self-treating methamphetamine withdrawal with prescription stimulants.

Methamphetamine versus cocaine: similarities and differences

The similarities are real, but “stimulant withdrawal” should not erase pharmacologic differences.

Fentanyl and opioid co-exposure change the safety picture

The modern U.S. stimulant supply exists in a polysubstance overdose environment.

CDC notes that cocaine and methamphetamine can be used alongside or exposed to illegally manufactured fentanyl [32-36].

The mortality data make opioid co-exposure impossible to treat as a side issue. In CDC SUDORS data covering January 2021 through June 2024 across 49 states and the District of Columbia, 73.0% of stimulant-involved overdose deaths co-involved opioids; the proportion was 79.1% for cocaine-involved deaths and 68.8% for methamphetamine-involved deaths [37]. The same report cautions against assuming all of this reflects accidental contamination: available drug-checking data rarely detected opioids in stimulant products, suggesting that intentional co-use of separate stimulant and opioid products accounts for much of the fatal overlap [37].

CDC clinical drug-testing data from 2025-2026 also show frequent co-detection of illicit stimulants with fentanyl in the sampled treatment population, although those data are not nationally representative [33,34].

This matters because:

• opioid toxicity can cause respiratory depression during what looks like a stimulant crash;
• opioid withdrawal can overlap stimulant withdrawal;
• naloxone can reverse opioid toxicity but does not treat stimulant toxicity;
• stimulant users may have little or no opioid tolerance.

Naloxone availability is therefore reasonable harm reduction for people exposed to an unpredictable illicit stimulant supply.

Stimulant-opioid co-use and contingency management

Treatment evidence is evolving.

A 2026 systematic review/meta-analysis found CM improved simultaneous stimulant-opioid abstinence outcomes in trials of stimulant-opioid co-use [22].

However, the included studies largely predated the fentanyl-dominant era.

That limitation matters: evidence from cocaine-plus-heroin studies should not automatically be treated as definitive for today's fentanyl-methamphetamine market.

Nutrition and weight recovery

Stimulants suppress appetite and can disrupt regular eating.

During withdrawal, appetite may rebound dramatically.

Recovery nutrition should focus on:

• regular meals;
• adequate calories;
• protein and micronutrients;
• hydration;
• treatment of dental disease and gastrointestinal problems;
• screening for food insecurity.

A sudden increase in appetite is not evidence that the metabolism is “damaged.” It is an expected part of recovery for many people.

Cognitive recovery: avoid both doom and hype

Methamphetamine use disorder is associated with average deficits in attention, executive function, learning, memory, and decision-making across studies [27,28].

A 2026 meta-analysis found these deficits remained detectable across observed abstinence windows in many domains, but rated certainty very low because of the underlying study designs [28].

That means two common claims are both too strong:

• “The brain permanently never recovers.”
• “Everything is back to normal after 90 days.”

The evidence supports variability and the need for longitudinal research.

Cue reactivity can outlast the crash

Craving is not merely a symptom of the first few days.

A 2026 fMRI systematic review found persistent alterations in reward, salience, and executive networks associated with cue reactivity and craving in abstinent methamphetamine users [29].

Environmental cues can include:

• people;
• neighborhoods;
• money;
• sex;
• paraphernalia;
• music;
• apps;
• specific times of day;
• sleep deprivation;
• conflict.

Recovery planning therefore has to change the environment, not just remove the drug.

Post-acute symptoms: use the term carefully

ASAM/AAAP recognizes post-acute symptoms including:

• depression;
• anxiety;
• insomnia;
• paranoia;

which may persist for weeks to months [1].

That does not create a universal disease clock.

Persistent symptoms can also reflect:

• primary depression or bipolar disorder;
• PTSD;
• ADHD;
• sleep disorder;
• psychosis;
• medication effects;
• malnutrition;
• homelessness or chronic stress;
• ongoing use of other substances.

A good recovery article validates persistence and keeps diagnostic curiosity alive.

“Dopamine detox” is not a medical treatment

The phrase is popular online but scientifically sloppy.

Ordinary activities do not “drain dopamine” in the same sense as chronic high-intensity stimulant exposure, and avoiding music, phones, sugar, sex, or entertainment has not been shown to reset dopamine receptors after methamphetamine or cocaine use.

Evidence-based recovery focuses on:

• stopping or reducing harmful stimulant exposure;
• sleep;
• nutrition;
• psychiatric care;
• behavioral treatment;
• contingency management;
• social stability;
• treating co-occurring disorders.

Treat co-occurring ADHD rather than pretending it disappears

ADHD is common in people with StUD.

ASAM/AAAP explicitly supports treating ADHD concurrently and notes that pharmacotherapy, including psychostimulants in appropriate patients, can be considered [1].

That requires careful monitoring when misuse risk is present.

Untreated ADHD can worsen organization, impulsivity, treatment attendance, and relapse risk.

The question is not “stimulants are bad, so ADHD stimulants are forbidden.” It is which treatment creates the best risk-benefit balance for this person.

Pregnancy and postpartum

Pregnancy adds fetal and maternal considerations but does not erase the need to treat the pregnant patient.

ASAM/AAAP recommends standard assessment of acute intoxication/withdrawal with attention to fetal well-being, coordinated prenatal care, psychosocial support, and individualized medication risk-benefit decisions [1].

Hypertension is particularly important because stimulant-induced hypertension can be difficult to distinguish from pregnancy-related hypertensive disease.

The postpartum period can also increase stress and return-to-use risk.

Adolescents and young adults

Developmental stage changes:

• impulsivity;
• family context;
• school/work disruption;
• treatment engagement;
• risk perception.

ASAM/AAAP recommends providing evidence-based stimulant treatment and harm reduction in a developmentally responsive way rather than withholding treatment because of age [1].

Recovery after stimulant-induced psychosis

When psychosis resolves after stimulant cessation, recurrence risk can remain.

Recovery planning should address:

• sleep;
• stimulant abstinence/reduction;
• cannabis and other psychosis-amplifying exposures;
• stress;
• psychiatric follow-up;
• medication reassessment.

If psychosis persists well beyond expected intoxication/withdrawal, clinicians should evaluate for primary psychotic illness and other causes.

Return to use after abstinence

Stimulant return-to-use does not create the same loss-of-opioid-tolerance overdose mechanism seen in OUD.

But risk can still be high because:

• cardiovascular tolerance is incomplete and unpredictable;
• product potency varies;
• fentanyl may be present;
• binge patterns can restart rapidly;
• sleep deprivation compounds toxicity;
• psychiatric symptoms can recur;
• the person may combine stimulants with opioids, benzodiazepines, or alcohol.

Recovery plans should therefore include what to do after a lapse rather than treating it as total failure.

Harm reduction when abstinence is not immediate

Evidence-informed harm reduction can include:

• avoiding solitary use when overdose risk is present;
• carrying naloxone because opioid exposure may be unexpected;
• using fentanyl test strips where available;
• avoiding mixing stimulants with opioids or other substances;
• reducing sleep-deprivation binges;
• hydration and cooling during stimulant exposure;
• seeking care for chest pain, severe headache, hyperthermia, psychosis, or neurologic symptoms;
• sterile injection supplies and infection prevention;
• regular HIV/hepatitis/STI testing where relevant;
• connecting to CM and treatment even if abstinence is not yet achieved [1,32-36].

Myths versus evidence

“Stimulant withdrawal is not real because it usually does not cause seizures.”

False. Withdrawal is a recognized syndrome; its major risks are mood, psychiatric, functional, and return-to-use related rather than the classic seizure/delirium pattern of alcohol or benzodiazepines [1,3-6].

“The crash is over after one long sleep.”

Often false. Hypersomnia may dominate early, but depression, craving, sleep disturbance, anxiety, and cognitive symptoms can continue [1,3].

“Your dopamine is permanently gone.”

Unsupported. Group-level neurobiological and cognitive differences are documented, but individual recovery trajectories are variable and incompletely characterized [27-30].

“Dopamine detoxing speeds brain recovery.”

Not established. There is no clinical evidence that avoiding ordinary rewarding activities resets stimulant-altered dopamine systems.

“There is no treatment because there is no FDA-approved medication.”

False. Contingency management has strong evidence and is the standard of care, with additional behavioral and selected off-label pharmacologic options [1,17-25].

“Naltrexone cures methamphetamine addiction.”

False. The strongest trial used naltrexone with bupropion, and the absolute response rate remained modest [9,10].

“All stimulant withdrawal is the same.”

Too broad. Cocaine, methamphetamine, amphetamine, routes of administration, dose patterns, sleep deprivation, and co-exposures materially alter the syndrome.

“If someone uses stimulants, prescribed ADHD treatment must be stopped.”

Not automatically. Co-occurring ADHD should be treated, with medication choice and monitoring individualized [1,31].

“A sleepy person after cocaine or meth use just needs to sleep it off.”

Potentially dangerous. Opioid co-exposure, head injury, stroke, infection, metabolic illness, or overdose can mimic a crash [1,32-36].

Evidence ledger

High-confidence conclusions

The strongest evidence supports:

• stimulant withdrawal is a real syndrome;
• early fatigue/somnolence and mood symptoms are common;
• suicidality and psychosis require active assessment;
• chest pain, stroke symptoms, hyperthermia, seizure, or altered consciousness should not be dismissed as withdrawal;
• there is no established medication for acute stimulant withdrawal;
• contingency management is the strongest evidence-based treatment for StUD;
• co-occurring psychiatric disorders should be treated;
• opioid co-exposure changes overdose risk and justifies naloxone-oriented harm reduction.

Moderate or evolving conclusions

Evidence is meaningful but not definitive for:

• naltrexone+bupropion for methamphetamine use disorder;
• mirtazapine for selected patients with methamphetamine use disorder;
• prescription psychostimulants for selected StUD populations under specialist care;
• medication strategies for cocaine use disorder;
• cognitive recovery rates;
• imaging-based recovery trajectories;
• the duration and boundaries of post-acute stimulant withdrawal.

Major evidence gaps

High-value unanswered questions include:

• Which patients are at highest suicide risk during the crash/withdrawal transition?
• What distinguishes transient stimulant-induced depression from a persistent mood disorder?
• Which medications best treat acute withdrawal symptoms without creating new harms?
• How can contingency management gains be sustained after incentives end?
• Which pharmacotherapies work for specific methamphetamine or cocaine phenotypes?
• What are the long-term cognitive recovery trajectories after sustained abstinence or major reduction?
• How does fentanyl-era stimulant-opioid co-use change treatment outcomes?
• What objective biomarkers distinguish intoxication, acute withdrawal, and post-acute recovery?
• How should prescription-stimulant discontinuation be managed in adults with legitimate ADHD treatment needs?
• Which sleep interventions improve both sleep and stimulant outcomes?

Related evidence on The Hippie Scientist

• Substance Use, Withdrawal & Recovery hub
• Benzodiazepine & Z-Drug Withdrawal: Complete Evidence Guide
• Alcohol Withdrawal & Recovery: Complete Evidence Guide
• Opioid Withdrawal & Recovery: Complete Evidence Guide
• Harm Reduction Foundations

What this article deliberately does not provide

This page does not provide:

• instructions for using prescription stimulants to self-treat illicit stimulant withdrawal;
• a “dopamine reset” supplement stack;
• advice on how to binge more safely or extend stimulant effects;
• dosing protocols for off-label StUD medications;
• instructions for combining stimulants with depressants to control the crash.

Those omissions are deliberate. The goal is to make withdrawal and recovery safer, not optimize stimulant use.

Bottom line

Stimulant withdrawal is usually not medically dangerous for the same reasons alcohol or benzodiazepine withdrawal can be, but it can still be a high-risk clinical period.

The first phase often brings exhaustion, sleepiness, appetite rebound, depression, anhedonia, irritability, and craving. The most important acute dangers are psychiatric and contextual: suicidality, persistent psychosis, severe depression, consequences of recent intoxication, and hidden opioid co-exposure [1,3,32-36].

There is no universal dopamine-reset timeline and no approved medication that reliably erases acute withdrawal. Symptoms can extend from days into weeks or months, especially sleep, mood, paranoia, craving, and cognitive complaints [1,27-30].

For long-term stimulant use disorder, contingency management has the strongest evidence and should be treated as a core therapy rather than an optional curiosity [1,17-25]. Medication evidence is improving—especially naltrexone plus bupropion and mirtazapine in specific methamphetamine populations—but remains narrower and less definitive than medication treatment for opioid use disorder [9-16].

The recovery benchmark is therefore not “sleep off the crash.” It is survive the psychiatric and medical risk window, restore sleep/nutrition/function, treat co-occurring illness, reduce overdose risk, and connect the person to treatment strong enough to compete with stimulant reinforcement over time.